Genmab: J&J har valgt ikke at udnytte option på HexaBody-CD38 (GEN3014), aktien 6% nede
10/3 15:28
Fra Genmab Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38 March 10, 2025 at 10:22 am EDT Share Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical development of HexaBody-CD38 Data validates clinical potential of […]...